Modality
Radioligand
MOA
HER2
Target
JAK2
Pathway
Sphingolipid
GBM
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
~Mar 2019
→ ~Jun 2020
Phase 2
Sep 2020
→ Nov 2028
Phase 2Current
NCT05995965
413 pts·GBM
2020-09→2028-11·Not yet recruiting
413 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-072.6y awayPh2 Data· GBM
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Not yet…
Catalysts
Ph2 Data
2028-11-07 · 2.6y away
GBM
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05995965 | Phase 2 | GBM | Not yet recr... | 413 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 |